Research

Multimodal Treatment Approaches for Basaloid Squamous Cell Carcinoma of the Larynx


 

Background

Basaloid squamous cell carcinoma (BSCC) is an aggressive laryngeal cancer with high recurrence and metastasis rates. Its rarity complicates diagnosis and optimal treatment selection, underscoring the significance of comprehensive data collection through national cancer registries. Historically, surgical intervention has been the primary approach to management.The RTOG 91-11 randomized trial catalyzed a paradigm shift, prioritizing laryngealpreserving treatments. The study provided evidence for radiotherapy in early-stage disease (stages 1-2) and combined chemoradiotherapy in advanced disease (stages 3-4). Consequently, organ preservation protocols gained traction, maintaining laryngeal anatomy while achieving comparable oncologic outcomes to total laryngectomy. This shift emphasizes exploring multimodal, laryngeal-sparing regimens to optimize quality of life without compromising disease control. However, further research utilizing large databases is needed to elucidate survival outcomes associated with these approaches.

Methods

We used the National Cancer Database to identify patients diagnosed with BSCC of the larynx (ICD-O-3 histology code 8083) between 2004-2019 (Nf1487). General patient characteristics were assessed using descriptive statistics. Survival was evaluated using Kaplan-Meier curves and log-rank tests. Significance was set at p< 0.05.

Results

For early-stage patients, the estimated survival was 93.179 months. Surgery demonstrated the most favorable outcome with a median survival of 100.957 months, significantly higher than non-surgical patients (85.895 months, p=0.028). Survival did not differ between patients who received only chemotherapy (p=0.281), radiation (p=0.326), or chemoradiation (p=0.919) and those received other treatment modalities. In late-stage patients, the estimated survival was 61.993 months. Surgery yielded the most favorable outcome with a median survival of 70.484 months, significantly higher than non-surgical patients (54.153 months, p< 0.001). Patients who received only chemotherapy (p< 0.001), radiation (p< 0.001) and chemoradiation (p=0.24) had a worse survival outcome compared to those who received other treatment modalities.

Conclusions

The study results indicate that surgical resection could potentially improve survival outcomes for patients diagnosed with advanced-stage laryngeal BSCC. Conversely, for those with earlystage BSCC, larynx-preserving treatment modalities such as radiation, chemotherapy or concurrent chemoradiation appear to achieve comparable survival rates to primary surgical management. These results highlight the importance of careful consideration of treatment modalities based on disease staging at initial presentation.

Recommended Reading

Clinical Controversy: Watch-and-Wait or Surgery in Rectal Cancer Near Complete Responders?
AVAHO
Do New Blood Tests for Cancer Meet the Right Standards?
AVAHO
Telehealth Research and Innovation for Veterans With Cancer (THRIVE): Understanding Experiences of National TeleOncology Service Providers
AVAHO
Registered Dietitian Staffing and Nutrition Practices in High-Risk Cancer Patients Across the Veterans Health Administration
AVAHO
Unexpected Findings: A Rare Case of Signet Ring Cell Adenocarcinoma in the Small Intestine
AVAHO
Impact of Stewardship Assistance Pilot Program for Veterans on Adherence and Persistence to Oral mCRPC Therapies
AVAHO
Baseline Patient-Reported Care Metrics in a VA Hematology/Oncology Clinic Prior to Implementation of the 4R (Right Information and Right Care for the Right Patient at the Right Time) Oncology Model
AVAHO
Cancer Cases, Deaths in Men Predicted to Surge by 2050
AVAHO
Creating a Urology Prostate Cancer Note, a National Oncology and Surgery Office Collaboration for Prostate Cancer Clinical Pathway Utilization
AVAHO
National Tele-Oncology High-Risk Breast Clinic Program
AVAHO